What you should know about Cervical Cancer
Thursday, February 16, 2017
Unlike many gynecologic cancers, there is a vaccination and screening test for cervical cancer, an important distinction in preventing and identifying the disease, according to Ursula Matulonis, MD, medical director of Gynecologic Oncology in Dana-Farber’s Susan F. Smith Center for Women’s Cancers, and Colleen Feltmate, MD, director of minimally invasive surgery in Gynecologic Oncology at Brigham and Women’s Hospital.
Wider Racial Gap Found in Cervical Cancer Deaths
Monday, January 23, 2017
Nonsurgical Management of Cervical Cancer: Locally Advanced, Recurrent, and Metastatic Disease, Survivorship, and Beyond
Tuesday, June 30, 2015
Despite the declining incidence of cervical cancer as a result of the introduction of screening programs, globally it remains a leading cause of cancer-related death in women. Outcomes for patients who are diagnosed with anything but early-stage disease remain poor.
11 Things You Never Knew to Ask Your Gyno About Cervical Cancer
Tuesday, January 13, 2015
But just because this gynecologic cancer occurs less frequently doesn’t mean it’s less deadly. In fact, cervical cancer was once the No. 1 leading cause of cancer death for women in the US. What’s worse? The disease is almost 100 percent preventable. This fact is especially chilling for Latinas, who have the highest incidence of cervical cancer and the second-highest death rate from the disease.
Half of young women unable to ‘locate vagina'
Tuesday, November 25, 2014
Half of young women are unable to properly label a vagina on a medical diagram, while 65 per cent have admitted they have a problem simply using the words vagina or vulva.
FDA approves Avastin to treat patients with aggressive and late-stage cervical cancer
Thursday, August 21, 2014
Avastin works by interfering with the blood vessels that fuel the development of cancerous cells. The new indication for cervical cancer is approved for use in combination with chemotherapy drugs paclitaxel and cisplatin or in combination with paclitaxel and topotecan.
Study finds genomic differences in types of cervical cancer
Monday, August 19, 2013
A new study has revealed marked differences in the genomic terrain of the two most common types of cervical cancer, suggesting that patients might benefit from therapies geared to each type’s molecular idiosyncrasies.........
.....The research was supported by grants from the American Cancer Society, the Conquer Cancer Foundation of the American Society of Clinical Oncology, the Team Maureen Cervical Cancer Fund, and the Friends of Dana-Farber Cancer Institute.